Pyruvate increases threshold for preconditioning in globally ischemic rat hearts. 1994

C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
Department of Cardiovascular Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.

Isolated rat hearts can be protected by preconditioning, although this has not been found when they are perfused with pyruvate. We addressed the question of whether pyruvate could increase the threshold for preconditioning in isolated rat hearts and whether this could be overcome with increased durations of ischemia. A protocol of four periods of 5 min of ischemic preconditioning (4 x 5 min) protected hearts (improved recovery of function, reduced lactate dehydrogenase release) not perfused with pyruvate from a subsequent 30-min period of global ischemia, but did not protect pyruvate-perfused hearts. Pilot studies indicated that hearts perfused in the presence of pyruvate must be ischemic for approximately 40% longer to produce equivalent ischemic damage in nonpyruvate-treated hearts. Thus the preconditioning period of 5 min was increased by approximately 40% to 7 min to produce equivalent degrees of preconditioning. Hearts preconditioned with the 4 x 7 min protocol with pyruvate were significantly protected against a subsequent severe global ischemia (enhanced recovery of function, reduced lactate dehydrogenase release). High-energy phosphates were measured at the end of the preconditioning protocol (before final global ischemia) to determine whether there was a correlation between cardioprotection and high-energy phosphate levels. There was no correlation between ATP, ADP, or AMP levels and the efficacy of preconditioning. However, an increase in creatine phosphate was associated with cardioprotection, although the importance of this in mediating preconditioning is doubtful. Thus the ability to precondition rat hearts is somewhat dependent on their energy source, but this appears to be due to changes in the severity of the ischemic preconditioning event.

UI MeSH Term Description Entries
D008297 Male Males
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011773 Pyruvates Derivatives of PYRUVIC ACID, including its salts and esters.
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016277 Ventricular Function, Left The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance. Left Ventricular Function,Function, Left Ventricular,Functions, Left Ventricular,Left Ventricular Functions,Ventricular Functions, Left

Related Publications

C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
August 1998, The Journal of thoracic and cardiovascular surgery,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
December 1996, Journal of molecular and cellular cardiology,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
June 1987, European journal of pharmacology,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
September 1997, Circulation,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
May 1995, The American journal of physiology,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
January 2015, International journal of clinical and experimental medicine,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
March 2009, International journal of cardiology,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
March 1998, Journal of the American College of Cardiology,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
September 1995, The Journal of clinical investigation,
C A Sargent, and S Dzwonczyk, and P Sleph, and M Wilde, and G J Grover
February 2001, European journal of pharmacology,
Copied contents to your clipboard!